食管-话题@MedSci

#食管#

815篇内容 | 2448人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1437716, encodeId=457b143e716f4, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, objectTitle=J Immunother Cancer：卡瑞利珠单抗+化疗作为局部晚期食管癌术前辅助治疗的疗效和安全性, objectType=article, longId=301810, objectId=b131301810c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b131301810c5, replyNumber=0, likeNumber=83, createdTime=2022-03-29, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b131301810c5, moduleTitle=J Immunother Cancer：卡瑞利珠单抗+化疗作为局部晚期食管癌术前辅助治疗的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b131301810c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1437720, encodeId=17cd143e720f5, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, objectTitle=再迎出海里程碑，百泽安®肺癌和食管癌上市许可申请获欧洲药品管理局受理, objectType=article, longId=301671, objectId=94873016e162, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94873016e162, replyNumber=0, likeNumber=66, createdTime=2022-03-27, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94873016e162, moduleTitle=再迎出海里程碑，百泽安®肺癌和食管癌上市许可申请获欧洲药品管理局受理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94873016e162)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1437715, encodeId=9575143e71565, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, objectTitle=Clin Cancer Res：ATTRACTION-3研究3年随访生存结果表明nivolumab较化疗改善晚期食管鳞状细胞癌（ESCC）患者预后, objectType=article, longId=301417, objectId=e1c330141efe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1c330141efe, replyNumber=0, likeNumber=32, createdTime=2022-03-24, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1c330141efe, moduleTitle=Clin Cancer Res：ATTRACTION-3研究3年随访生存结果表明nivolumab较化疗改善晚期食管鳞状细胞癌（ESCC）患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1c330141efe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1437714, encodeId=3061143e71424, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, objectTitle=Cancer Immunol Immunother：Camrelizumab（卡瑞利珠单抗）联合阿帕替尼和S1作为二线治疗晚期胃或胃食管交界处腺癌的疗效, objectType=article, longId=301252, objectId=1d863012523c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d863012523c, replyNumber=0, likeNumber=81, createdTime=2022-03-22, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d863012523c, moduleTitle=Cancer Immunol Immunother：Camrelizumab（卡瑞利珠单抗）联合阿帕替尼和S1作为二线治疗晚期胃或胃食管交界处腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d863012523c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1437713, encodeId=7f7b143e71304, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, objectTitle=胃食管反流，30个问题（超全大汇总）, objectType=article, longId=301194, objectId=66bb30119445, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66bb30119445, replyNumber=0, likeNumber=78, createdTime=2022-03-21, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66bb30119445, moduleTitle=胃食管反流，30个问题（超全大汇总）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66bb30119445)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1437712, encodeId=039f143e71230, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, objectTitle=Clin Cancer Res：纳武单抗可显著延长晚期食管鳞癌的长期生存期, objectType=article, longId=301037, objectId=1d0d30103eaf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d0d30103eaf, replyNumber=0, likeNumber=112, createdTime=2022-03-19, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d0d30103eaf, moduleTitle=Clin Cancer Res：纳武单抗可显著延长晚期食管鳞癌的长期生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d0d30103eaf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1437711, encodeId=b31a143e7117d, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, objectTitle=BMC Cancer：双周SOX方案一线治疗中国老年晚期或转移性G/GEJ(胃或胃食管交界处癌)的疗效和安全性, objectType=article, longId=300556, objectId=17eb300556a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17eb300556a6, replyNumber=0, likeNumber=77, createdTime=2022-03-13, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17eb300556a6, moduleTitle=BMC Cancer：双周SOX方案一线治疗中国老年晚期或转移性G/GEJ(胃或胃食管交界处癌)的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17eb300556a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1437710, encodeId=4ab9143e71050, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, objectTitle=Clin Cancer Res：陈明教授团队发现不可手术的食管鳞状细胞癌（ESCC）同步放化疗中使用放疗剂量为50Gy更合适, objectType=article, longId=300448, objectId=e70c30044809, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e70c30044809, replyNumber=0, likeNumber=82, createdTime=2022-03-12, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e70c30044809, moduleTitle=Clin Cancer Res：陈明教授团队发现不可手术的食管鳞状细胞癌（ESCC）同步放化疗中使用放疗剂量为50Gy更合适, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e70c30044809)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1437709, encodeId=ffc6143e709f9, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, objectTitle=Ther Adv Med Oncol：以人群为基础研究评估可切除II/III期食管或胃食管交界处癌患者的临床预后, objectType=article, longId=300086, objectId=ce6c30008640, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce6c30008640, replyNumber=0, likeNumber=70, createdTime=2022-03-06, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce6c30008640, moduleTitle=Ther Adv Med Oncol：以人群为基础研究评估可切除II/III期食管或胃食管交界处癌患者的临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce6c30008640)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1437708, encodeId=551a143e70868, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, objectTitle=CHMP支持Opdivo治疗食管、尿路上皮癌, objectType=article, longId=299738, objectId=b3b3299e38c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3b3299e38c5, replyNumber=0, likeNumber=77, createdTime=2022-03-01, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3b3299e38c5, moduleTitle=CHMP支持Opdivo治疗食管、尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3b3299e38c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1437707, encodeId=a901143e707cf, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, objectTitle=中医治疗的食管癌，出路在哪里？, objectType=article, longId=299595, objectId=ce542995956e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce542995956e, replyNumber=0, likeNumber=60, createdTime=2022-02-26, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce542995956e, moduleTitle=中医治疗的食管癌，出路在哪里？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce542995956e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1437706, encodeId=38f9143e7065c, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, objectTitle=Oncologist：Toripalimab（特瑞普利单抗）联合紫杉醇+卡铂新辅助治疗可切除局部晚期食管鳞状细胞癌的疗效, objectType=article, longId=299451, objectId=fc31299451e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc31299451e9, replyNumber=0, likeNumber=34, createdTime=2022-02-24, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc31299451e9, moduleTitle=Oncologist：Toripalimab（特瑞普利单抗）联合紫杉醇+卡铂新辅助治疗可切除局部晚期食管鳞状细胞癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc31299451e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1437705, encodeId=f390143e705c0, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, objectTitle=食管鳞癌术后随访中国胸外科专家共识, objectType=article, longId=299416, objectId=cd442994164b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd442994164b, replyNumber=0, likeNumber=35, createdTime=2022-02-24, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd442994164b, moduleTitle=食管鳞癌术后随访中国胸外科专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd442994164b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1437704, encodeId=a917143e704f0, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, objectTitle=浙江省经食管心脏电生理技术操作与诊断规范（2021 修订版）, objectType=article, longId=299344, objectId=162529934407, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=162529934407, replyNumber=0, likeNumber=76, createdTime=2022-02-23, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=162529934407, moduleTitle=浙江省经食管心脏电生理技术操作与诊断规范（2021 修订版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=162529934407)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1437703, encodeId=0a53143e70364, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, objectTitle=Lancet Oncol：纳武单抗联合奥沙利铂化疗一线治疗晚期或复发性胃或胃食管交界癌, objectType=article, longId=295669, objectId=d4cf2956690e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4cf2956690e, replyNumber=0, likeNumber=65, createdTime=2022-02-16, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4cf2956690e, moduleTitle=Lancet Oncol：纳武单抗联合奥沙利铂化疗一线治疗晚期或复发性胃或胃食管交界癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4cf2956690e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1437702, encodeId=bd14143e7029a, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, objectTitle=Thorac Cancer：局部晚期可切除食管鳞状细胞癌(ESCC)使用脂质体紫杉醇+铂类方案作为新辅助化疗的疗效和安全性, objectType=article, longId=295185, objectId=293529518574, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=293529518574, replyNumber=0, likeNumber=40, createdTime=2022-02-07, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=293529518574, moduleTitle=Thorac Cancer：局部晚期可切除食管鳞状细胞癌(ESCC)使用脂质体紫杉醇+铂类方案作为新辅助化疗的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=293529518574)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1437701, encodeId=c60e143e70149, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, objectTitle=NEJM：纳武单抗联合治疗对晚期食管鳞状细胞癌的疗效分析, objectType=article, longId=295127, objectId=119b29512e22, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=119b29512e22, replyNumber=0, likeNumber=59, createdTime=2022-02-06, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=119b29512e22, moduleTitle=NEJM：纳武单抗联合治疗对晚期食管鳞状细胞癌的疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=119b29512e22)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1437700, encodeId=4a0b143e70035, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, objectTitle=BMC Cancer：淋巴结检查数目（NELNs）对病理分期为 T1-3N0M0的食管鳞状细胞癌患者预后影响, objectType=article, longId=295098, objectId=2c292950982d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c292950982d, replyNumber=0, likeNumber=71, createdTime=2022-02-05, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c292950982d, moduleTitle=BMC Cancer：淋巴结检查数目（NELNs）对病理分期为 T1-3N0M0的食管鳞状细胞癌患者预后影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c292950982d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1437699, encodeId=69dd143e69910, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, objectTitle=Molecular Cancer：临床试验：唾液外泌体小RNA可作为食管癌检测和预后标志物, objectType=article, longId=294648, objectId=f8982946481a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8982946481a, replyNumber=0, likeNumber=61, createdTime=2022-01-26, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8982946481a, moduleTitle=Molecular Cancer：临床试验：唾液外泌体小RNA可作为食管癌检测和预后标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8982946481a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1437698, encodeId=ff45143e6986f, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, objectTitle=Lancet Gastroenterol Hepatol：郑大一附院王峰教授CAP 02研究显示卡瑞利珠单抗联合阿帕替尼二线治疗晚期食管鳞癌疗效显著, objectType=article, longId=293995, objectId=58f82939954d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58f82939954d, replyNumber=0, likeNumber=82, createdTime=2022-01-16, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58f82939954d, moduleTitle=Lancet Gastroenterol Hepatol：郑大一附院王峰教授CAP 02研究显示卡瑞利珠单抗联合阿帕替尼二线治疗晚期食管鳞癌疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58f82939954d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

食管

2020-05-29

zhouqu_8 (审核中...)

前往app查看评论内容

#食管#

J Immunother Cancer：卡瑞利珠单抗+化疗作为局部晚期食管癌术前辅助治疗的疗效和安全性

2022-03-29

zhouqu_8 (审核中...)

前往app查看评论内容

#食管#

再迎出海里程碑，百泽安®肺癌和食管癌上市许可申请获欧洲药品管理局受理

2022-03-27

zhouqu_8 (审核中...)

前往app查看评论内容

#食管#

Clin Cancer Res：ATTRACTION-3研究3年随访生存结果表明nivolumab较化疗改善晚期食管鳞状细胞癌（ESCC）患者预后

2022-03-24

zhouqu_8 (审核中...)

前往app查看评论内容

#食管#

Cancer Immunol Immunother：Camrelizumab（卡瑞利珠单抗）联合阿帕替尼和S1作为二线治疗晚期胃或胃食管交界处腺癌的疗效

2022-03-22

zhouqu_8 (审核中...)

前往app查看评论内容

#食管#

胃食管反流，30个问题（超全大汇总）

2022-03-21

zhouqu_8 (审核中...)

前往app查看评论内容

#食管#

Clin Cancer Res：纳武单抗可显著延长晚期食管鳞癌的长期生存期

2022-03-19

zhouqu_8 (审核中...)

前往app查看评论内容

#食管#

BMC Cancer：双周SOX方案一线治疗中国老年晚期或转移性G/GEJ(胃或胃食管交界处癌)的疗效和安全性

2022-03-13

zhouqu_8 (审核中...)

前往app查看评论内容

#食管#

Clin Cancer Res：陈明教授团队发现不可手术的食管鳞状细胞癌（ESCC）同步放化疗中使用放疗剂量为50Gy更合适

2022-03-12

zhouqu_8 (审核中...)

前往app查看评论内容

#食管#

Ther Adv Med Oncol：以人群为基础研究评估可切除II/III期食管或胃食管交界处癌患者的临床预后

2022-03-06

zhouqu_8 (审核中...)

前往app查看评论内容

#食管#

CHMP支持Opdivo治疗食管、尿路上皮癌

2022-03-01

zhouqu_8 (审核中...)

前往app查看评论内容

#食管#

中医治疗的食管癌，出路在哪里？

2022-02-26

zhouqu_8 (审核中...)

前往app查看评论内容

#食管#

Oncologist：Toripalimab（特瑞普利单抗）联合紫杉醇+卡铂新辅助治疗可切除局部晚期食管鳞状细胞癌的疗效

2022-02-24

zhouqu_8 (审核中...)

前往app查看评论内容

#食管#

食管鳞癌术后随访中国胸外科专家共识

2022-02-24

zhouqu_8 (审核中...)

前往app查看评论内容

#食管#

浙江省经食管心脏电生理技术操作与诊断规范（2021 修订版）

2022-02-23

zhouqu_8 (审核中...)

前往app查看评论内容

#食管#

Lancet Oncol：纳武单抗联合奥沙利铂化疗一线治疗晚期或复发性胃或胃食管交界癌

2022-02-16

zhouqu_8 (审核中...)

前往app查看评论内容

#食管#

Thorac Cancer：局部晚期可切除食管鳞状细胞癌(ESCC)使用脂质体紫杉醇+铂类方案作为新辅助化疗的疗效和安全性

2022-02-07

zhouqu_8 (审核中...)

前往app查看评论内容

#食管#

NEJM：纳武单抗联合治疗对晚期食管鳞状细胞癌的疗效分析

2022-02-06

zhouqu_8 (审核中...)

前往app查看评论内容

#食管#

BMC Cancer：淋巴结检查数目（NELNs）对病理分期为 T1-3N0M0的食管鳞状细胞癌患者预后影响

2022-02-05

zhouqu_8 (审核中...)

前往app查看评论内容

#食管#

Molecular Cancer：临床试验：唾液外泌体小RNA可作为食管癌检测和预后标志物

2022-01-26

zhouqu_8 (审核中...)

前往app查看评论内容

#食管#

Lancet Gastroenterol Hepatol：郑大一附院王峰教授CAP 02研究显示卡瑞利珠单抗联合阿帕替尼二线治疗晚期食管鳞癌疗效显著

2022-01-16

科室
- - 订阅+
  - 更多科室
工具
服务